Anthropic shares early results from drug-development partnerships

Anthropic says its scientists have spent the past few months in research partnerships with six organizations developing new medicines (BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group), and have begun drug discovery efforts of their own. In a blog post it shares early results and says it has learned how Claude can support the many stages of drug development. The post also describes how this work fits Anthropic's wider ambitions in the life sciences.

Anthropic reports, among other results:

• Generate Biomedicines: scientists using Claude Code proposed a CAR T-cell design about 70% shorter than the standard one, which in lab tests produced roughly 10 times as many receptors.
• Divergence Labs: Claude generated about 35,000 antibody designs in about a month; early tests found three that bind IgE and 20 that dislodge it.
• BigHat Biosciences: about 1,010 variants tested in about 10 weeks; the best bound more than 10x more tightly than the originals.
• Enveda: Claude caught all 11 issues human reviewers had found in 1,061 pages of manufacturing records, flagged seven they missed, and cut review time by 89%.

The results are Anthropic's own account.